Community-acquired pneumonia

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 12, Issue 6, 2012, Pages 538-543

  Brown, Jeremy S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Biomarkers; Community acquired pneumonia; Infectious disease

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; BIOLOGICAL MARKER; CARBAPENEM DERIVATIVE; CEFUROXIME; CELL SURFACE PROTEIN; CEPHALOSPORIN DERIVATIVE; COMPLEMENT RECEPTOR; DEFENSIN; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTOFERRIN; LINEZOLID; LYSOZYME; MACROLIDE; MANNOSE RECEPTOR; MOXIFLOXACIN; OPSONIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; SCAVENGER RECEPTOR; TEICOPLANIN; VANCOMYCIN;

ACTINOMYCES; ADAPTIVE IMMUNITY; AGE; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS; ATYPICAL MYCOBACTERIUM; BRONCHIECTASIS; CHLAMYDOPHILA PNEUMONIAE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYSTIC FIBROSIS; DISEASE SEVERITY; FUSOBACTERIUM NECROPHORUM; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; INFLUENZA A; INNATE IMMUNITY; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; LUNG ALVEOLUS MACROPHAGE; MORAXELLA CATARRHALIS; MORTALITY; MUCOCILIARY CLEARANCE; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; NEUTROPHIL; PLEURA EFFUSION; PSEUDOMONAS AERUGINOSA; SEPSIS; SMOKING; SNEEZING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; UNITED KINGDOM;

AGE FACTORS; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; RISK FACTORS;

EID: 84873892810     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.12-6-538     Document Type: Article

References (20)

1. Trotter CL, Stuart JM, George R et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008;14:727-33.
2. Woodhead M, Welch CA, Harrison DA et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17, 869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006;10:S1.
3. Grijalva CG, Zhu Y, Nuorti JP et al. Emergence of parapneumonic empyema in the USA. Thorax 2011;66:663-8.
4. Lim WS, Woodhead M, British Thoracic Society. British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax 2011;66:548-9.
5. Lim WS, Macfarlane JT, Boswell TC et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001;56:296-301.
6. Boyd AR, Orihuela CJ. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis 2011;2:487-500.
7. Baxendale HE, Brown JS. Mechanisms of immune protection to pneumococcal infection in the young and the elderly. In: Thiel A (ed), Immunosenescence. Basel: Springer Basel AG, 2012:85-126.
8. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64:iii1-55.
9. Brown JS. Biomarkers and community-acquired pneumonia. Thorax 2009;64:556-8.
10. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-25.
11. Chalmers JD, Singanayagam A, Murray MP et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009;64:592-7.
12. Tessmer A, Welte T, Martus P et al. Impact of intravenous lactam/macrolide versus lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009;63:1025-33.
13. Chalmers JD, Singanayagam A, Murray MP et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7.
14. Meijvis SC, Hardeman H, Remmelts HH et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:2023-30.
15. Blackburn RM, Henderson KL, Lillie M et al. Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007-March 2010). Thorax 2011;66:389-95.
16. Chalmers JD, Singanayagam A, Akram AR et al. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011;66:416-23.
17. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
18. Klapdor B, Ewig S, Pletz MW et al. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J 2012;39:1156-61.
19. Almirall J, Gonzalez CA, Balanzo X et al. Proportion of communityacquired pneumonia cases attributable to tobacco smoking. Chest 1999;116:375-9.
20. Moberley SA, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;23:CD000422.